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Abstract
Purpose: In proton therapy, the potential of using high-dose rates in the can-
cer treatment is being explored. High-dose rates could improve efficiency and
throughput in standard clinical practice, allow efficient utilization of motion mit-
igation techniques for moving targets, and potentially enhance normal tissue
sparing due to the so-called FLASH effect. However, high-dose rates are dif-
ficult to reach when lower energy beams are applied in cyclotron-based pro-
ton therapy facilities, because they result in large beam sizes and divergences
downstream of the degrader, incurring large losses from the cyclotron to the
patient position (isocenter). In current facilities, the emittance after the degrader
is reduced using circular collimators; however, this does not provide an opti-
mal matching to the acceptance of the following beamline, causing a low trans-
mission for these energies. We, therefore, propose to use a collimation system,
asymmetric in both beam size and divergence, resulting in symmetric emittance
in both beam transverse planes as required for a gantry system. This new emit-
tance selection, together with a new optics design for the following beamline and
gantry, allows a better matching to the beamline acceptance and an improve-
ment of the transmission.
Methods: We implemented a custom method to design the collimator sizes
and shape required to select high emittance, to be transported by the following
beamline using new beam optics (designed with TRANSPORT) to maximize
acceptance matching. For predicting the transmission in the new configuration
(new collimators + optics), we used Monte Carlo simulations implemented in
BDSIM, implementing a model of PSI Gantry 2 which we benchmarked against
measurements taken in the current clinical scenario (circular collimators + clin-
ical optics).
Results: From the BDSIM simulations,we found that the new collimator system
and matching beam optics results in an overall transmission from the cyclotron
to the isocenter for a 70 MeV beam of 0.72%. This is an improvement of almost
a factor of 6 over the current clinical performance (0.13% transmission). The
new optics satisfies clinical beam requirements at the isocenter.
Conclusions: We developed a new emittance collimation system for PSI’s
PROSCAN beamline which, by carefully selecting beam size and divergence
asymmetrically, increases the beam transmission for low-energy beams in
current state-of -the-art cyclotron-based proton therapy gantries. With these
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improvements, we could predict almost 1% transmission for low-energy beams
at PSI’s Gantry 2. Such a system could easily be implemented in facilities
interested in increasing dose rates for efficient motion mitigation and FLASH
experiments alike.
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1 INTRODUCTION
Over the past two decades, proton therapy experienced
remarkable developments and has become a credible
option in radiotherapy to treat certain types of can-
cers. The most advanced, and nowadays the most used
method to deliver the dose is spot scanning or pencil
beam scanning (PBS)1,2 first introduced on a gantry in
a clinical setting at PSI in the 1990s. PBS typically pro-
vides improved dose conformity and healthy tissue spar-
ing when compared to equivalent photon plans.3–5 How-
ever, PBS is especially prone to uncertainties caused by
anatomical changes and motion during the treatment,
which may compromise its effectiveness.6–8 Hence, the
use of this technology is limited in the case of moving
tumors. Such treatments will necessarily require some
means for mitigating the interplay effect between the
motions in the patient and the beam delivery,9 the most
common motion mitigation techniques being breath-
hold,10,11 rescanning,12–15 and gating.16
Treatment delivery time with PBS depends both on
the beam-on time and the dead time (the time required
to change energy layers and/or lateral position) between
pencil beams. As such, PBS irradiation with high-
intensity beams will reduce beam-on time and thus
shorten total delivery times, making motion mitigation
techniques such as breath-hold or gating more efficient
and patient-friendly. Additionally, higher beam intensities
will permit efficient delivery of hypo-fractionated treat-
ments and will be an important enabler of proton FLASH
techniques.17–19
Most of the proton therapy facilities use a cyclotron,
which extracts proton beams at fixed energy. However,
to spread the dose over the depth of the tumor, differ-
ent beam energies are needed for the treatment (70–
230 MeV). In a cyclotron-based facility, the energy is
lowered by passing the beam through energy-degrading
material(s) (so-called energy degraders). However, due
to scattering in the degrader, for low-energy beams,
the emittance after the degrader is in the range of
few hundreds of π*mm*mrad.20,21 Additionally, due to
range straggling in the degrader, the momentum spread
of the beam will also increase. Therefore, to minimize
beam losses in the beamline, it is necessary to use
beam emittance selection collimators after the degrader
and momentum selection slits in the energy selection
system (ESS) to restrict the emittance and momen-
tum spread to the requirement of the following beam-
line or gantry.20,22 Currently, all cyclotron-based proton
therapy facilities transport a maximum emittance of 30
π*mm*mrad through the beamline22–27 (in this work,
beam sizes,divergences,and emittances are expressed
as 2σ values), which limits the transmission of low-
energy beams.For example,for the lower energies trans-
ported by the Gantry 2 at our institute (70–100 MeV),
transmission from the cyclotron to the isocenter is of the
order of only 0.1%, limiting beam intensity and there-
fore increasing treatment times, particularly for superfi-
cial tumors.
One way to achieve higher intensity beams at the
isocenter is to transport a higher emittance through the
following beamline and gantry. For example, in a beam
optics study, we have recently shown the potential of
allowing higher emittance to be transported through the
gantry using a larger beam size and smaller divergence
at the gantry entrance.28,29 In this study, we propose to
extend this transmission increase to the beam trans-
port line between degrader and gantry. Such a solution
should minimize transmission losses through the whole
beam transport,while still achieving clinically acceptable
beams at the isocenter.
For proton beam delivery with a gantry, it is required
to have the same beam properties at the isocenter for
all gantry angles. The most straightforward method to
achieve this is to have the same emittance (same beam
size and divergence) in both planes at the entrance of
the gantry.24 In general, in most cyclotron-based gantry
facilities, two round-shaped collimators, positioned after
the degrader, are used (designated as C1 and C2 in
Figure 1) which then provide the same beam size and
divergence in both planes, which is then symmetrically
imaged to the gantry entrance point.22,24–26,30,31 Due to
the alternating focusing signs of quadrupole lenses and
bending magnets, the requirements for beam size and
beam divergence at the start of the beam transport after
the degrader can be quite different for obtaining a maxi-
mum transmission and symmetric emittance. A round-
shaped collimator limits the emittance in both planes
in the same way, to achieve the symmetric emittance
requirement, but at the same time, it limits the emittance
in one plane more than necessary.
In this paper, we propose an emittance selection
based on asymmetric beam size and divergence selec-
tion and demonstrate its impact on transmissions
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F IGURE 1 Schematic representation of the PROSCAN beam line’s energy selection system. (Q = Quadrupole magnet, D = Dipole/Bending
magnet, C1 = Beam size selection collimator, C2 = Beam divergence selection collimator and, M= Beam current and beam profile monitor)
through simulations on the PSI proton therapy facility
PROSCAN.32 Using asymmetric collimation, a higher
(but still symmetric) beam emittance can be transported
through the beamline. To calculate the transmission
improvements of this design, we have performed Monte
Carlo simulations using BDSIM33 and have validated
the model using measurements performed at the PSI’s
Gantry 2 facility. After reaching a satisfactory descrip-
tion from the BDSIM model, we have used it to predict
the performance of the new collimator scheme in our
beamline. As we mainly want to improve transmission
for low-energy beams, we focus here only on the lowest
energy transported through our gantry (70 MeV). How-
ever, as all proton therapy facilities worldwide have simi-
lar limitations of maximum beam size in one transverse
plane and maximum divergence in another transverse
plane, we expect the method described in this paper to
be applicable to other cyclotron-driven facilities as well.
2 MATERIALS AND METHODS
2.1 Reference beam optics
The reference beam optics (currently used at PSI) of
the PROSCAN beamline were designed to have point-
to-point imaging from the degrader exit at beam size
selection collimator C1 (as shown in Figure 1) to the cou-
pling point of Gantry 2 with intermediate images. Colli-
mator C1 defines a 3 mm beam size, while collimator
C2 defines a 10 mrad divergence in both planes. The
beam optics has then been designed such that all mag-
net settings scale similarly with the beam momentum set
by the ESS. The gantry beam optics was also designed
to provide a point-to-point focus in both planes with a
1:1 imaging from the coupling point of the gantry to the
isocenter. The system is designed such that it provides
complete achromaticity of the transported beam in both
the beam transport line and in the gantry.
With the reference beam optics,we lose almost 98.5%
beam in the degrader and the collimator system (i.e.,
until M2) due to the only 30 π*mm*mrad emittance
resulting from the round collimators C1 and C2. In addi-
tion, due to the momentum selection slits necessary to
match the momentum spread of the beam to the beam-
line acceptance (Δp/p = ± 1%),we end up losing almost
99.77% beam by the time the beam reaches M3 at the
end of the ESS. The beam transport from the end of
the ESS to the coupling point however is very efficient
(almost zero losses). Finally, there is local transmission
of about 58% through the gantry. As such, the overall
transmission from the cyclotron to the isocenter is in the
order of 0.1%.
2.2 Required aperture sizes of the
asymmetric collimators
The main requirement of the emittance selection colli-
mators is to select the same emittance in both trans-
verse planes. We illustrate how this is performed on our
beamline (the ESS is schematically shown in Figure 1).
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F IGURE 2 Beam optics transporting 30 π*mm*mrad (3 mm beam size and 10 mrad divergence) in X-plane and 81 π*mm*mrad (3 mm, 27
mrad) in Y-plane through ESS. Beam envelope shows the beam size in 2-sigma values and the dispersion (dashed line) (The lower half shows
beam envelope in X-plane (bending plane) and the upper half shows envelope in Y-plane
TABLE 1 Required aperture radius of collimator C1 and C2 to
achieve 100 π*mm*mrad emittance in both planes
Collimator C1 radius (mm) Collimator C2 radius (mm)
X-plane Y-plane X-plane Y-plane
13.5 3.5 12.4 33.5
After the degrader, quadrupole Q4, the first quadrupole
after the degrader, is used to focus the beam in the ver-
tical (Y) plane. As quadrupole Q4 focuses the beam in
the Y-plane, it will defocus the beam in the horizontal (X)
plane. However, although defocused in the X-plane, the
beam size in the X-plane is limited by the aperture of the
following quadrupole Q5, leading to different maximum
divergence acceptances in both planes. With the 3 mm
beam size defined by collimator C1, the maximum possi-
ble divergences are 27 mrad in the Y-plane and 10 mrad
in the X-plane (Figure 2). In the Y-plane however, the
beamline allows a divergence almost three times higher
compared to the X-plane.
As the Gantry 2 can transport 100 π*mm*mrad
emittance,28 we have designed the collimator system
C1–C2 to select 100 π*mm*mrad in both planes too.We,
therefore, selected the beam divergence selection colli-
mator (C2) aperture such, to have the maximum accept-
able divergences in both planes, being 10 mrad and 27
mrad in the X and Y-plane, respectively. To also obtain
equal emittance in both planes, the beam size in the Y-
plane must be three times smaller than the beam size
in the X-plane. For this, we design collimator C1 such
that it selects a 10 mm beam size in the X-plane, and a
3.7 mm beam size in the Y-plane (Tables 1 and 2). The
used collimator apertures are given in Table 1. As we
first cut the beam using collimator C1, the shape of the
TABLE 2 Required beam sizes from collimator C1 and
divergences from collimator C2 to achieve 100 π*mm*mrad









X-plane 10 10 100
Y-plane 3.7 27 100
beam after the collimator is not Gaussian. Therefore, to
optimize the aperture of collimator C1 an iterative pro-
cess of testing different collimator apertures and deter-
mining their equivalent Gaussian parameters was per-
formed until the required beam size after the collimator
was reached.
2.3 New beam optics design with
asymmetric collimators
The beam optics has been designed by using the matrix
formalism code TRANSPORT.34 To design new beam
optics for the PROSCAN beamline to transport the
higher emittance (100 π*mm*mrad) resulting from the
use of asymmetric collimators, we used similar point-
to-point imaging as used in the reference beam optics.
However, to maximize the transmission through the
beamline and gantry, we have adapted the imaging fac-
tors for the new beam optics. As this starts with different
beam sizes in the two transverse planes at collimator
C1,different imaging in both planes is needed to achieve
the same beam size (16 mm) at the coupling point. For
the fixed part of the beamline (before the gantry), we
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F IGURE 3 Results of beam profile measurements. The measured profiles are shown in red (light line), the BDSIM simulation results in
black (dark line)
have used 1:2 imaging in the X-plane and 1:5 imag-
ing in the Y-plane between collimator C1 and the cou-
pling point. The Gantry 2 beam optics is then set at 2:1
imaging between the gantry coupling point and the
isocenter to get 8 mm beam size at the isocenter image
point (in vacuum). The momentum spread of the beam
is similar to the reference beam optics.
2.4 Monte Carlo simulations
TRANSPORT cannot predict beam losses along the
beamline. To calculate the transmission of the new
beam optics, Monte Carlo simulations, based on beam-
line settings optimized with TRANSPORT, are required.
In this work, these have been performed using the
BDSIM 1.4.133 Monte Carlo simulation toolkit. BDSIM
is based on the Geant4 toolkit [16] and is capable
of simulating a wide variety of beamline components
and magnets with Geant4 geometry, and can predict
beam losses in particle accelerator/beamline compo-
nents with high accuracy.35 We have therefore built
a model of PSI’s PROSCAN beamline and Gantry
2 in BDSIM. The calculations have been performed
with the physics list based on recommended modules
for proton therapy (G4EmStandardPhysics_option4,
G4HadronPhysicsQGSP_BIC_HP, G4StoppingPhysics,
G4HadronElasticPhysicsHP, G4EmStandardPhysics-
WVI).36–40 BDSIM has then been used to calcu-
late the beam losses along the beamline, which
can then be compared with relevant experimental
data. To minimize statistical error, simulations with
10 million initial particles have been performed. To
experience the systematic uncertainty due to the
choice of the physics model in transmission calcula-
tion, we repeated the simulations using two different
physics models, G4HadronPhysicsQGSP_BIC_AllHP
and G4HadronPhysicsQBBC. Transmission differences
between the two physics models were within ±3%.Post-
processing of the simulation data has been performed
using ROOT v6.2241 and MATLAB v9.642 scripts.
3 RESULTS
3.1 Validation of BDSIM model against
measurement
In the PROSCAN beamline, there are many strip cham-
ber monitors along the beamline which measure the pro-
files and the current (= intensity) of the beam.43 The
BDSIM simulations of the reference beam optics, sim-
ulated signals in all profile monitors which could then
be compared to experimental data. The profiles of three
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F IGURE 4 Beam envelope from BDSIM simulation for PSI’s reference beam optics for 70 MeV beam. The lower half shows the beam
envelope in X-plane (bending plane) and the upper half shows the envelope in Y-plane. Yellow squares show measured beam size with black
error bars (gaussian fitting error)
TABLE 3 Comparison between measured and simulated transmission along the beamline for reference beam optics. The transmission is
expressed as a percentage of the beam intensity extracted from the cyclotron
M1 M2 M3 Coupling point isocenter
BDSIM Simulation 10 ± 0.3% 1.47 ± 0.04% 0.23 ± 0.007% 0.22 ± 0.007% 0.13 ± 0.004%
Measurements 10.1 ± 0.7% 1.46 ± 0.1% 0.21 ± 0.015% 0.21 ± 0.015% 0.13 ± 0.002%
important monitors (elements M1–3 shown in Figure 1),
located behind the collimators (C1 and C2) and the ESS,
where most of the beam is lost, are shown in Figure 3.
For each monitor, the particle distribution predicted by
the BDSIM is directly compared with the measured pro-
file. Measured and simulated profiles were found to be
in good agreement.
Besides the qualitative comparison in Figure 3, an
analysis was performed of the beam transport from
cyclotron exit to the isocenter of the Gantry 2, as shown
in Figure 4. This compares the beam size calculated
with BDSIM with measurements performed at the profile
monitors along the PROSCAN beamline. For these, the
measured beam size has been extracted using a Gaus-
sian fit, indicating that simulated and measured beam
sizes also match along the beamline. Note that even
when the beam profiles are non-Gaussian, the beam
shape is always similar in both simulations and mea-
surements.
Transmission measurements through the ESS have
been performed at three different beamline positions
using current monitors M1, M2, and M3. In addition,
transmission has also been measured at the coupling
point (gantry entrance) and isocenter.
As shown in Table 3, transmission calculation of refer-
ence beam optics using BDSIM simulation matches the
measured transmission. The overall transmission from
the cyclotron to the isocenter is in the order of 0.1%.
The agreement between the measurement results and
the simulated profiles and transmission, as listed in Fig-
ures 3 and 4, and Table 3, indicates that the accuracy of
the simulated transmissions is much better than 10%,
sufficient for the purpose of this work.
3.2 Transmission improvements with
asymmetric collimators
Figure 5 compares the reference beam optics (30
π*mm*mrad emittance) using round collimators and with
the beam optics using elliptically shaped asymmetric
collimators (100 π*mm*mrad). Although this new beam
NEW EMITTANCE SELECTION COLLIMATOR 7
F IGURE 5 Part (a) shows reference beam optics with two round-shaped symmetric phase space selection collimators. Part (b) shows
newly developed beam optics with two asymmetric phase space selection collimators. Beam envelope shows the beam size in 2-sigma values
and the dispersion (dashed line) along the PROSCAN beamline and Gantry 2 (The lower half shows beam envelope in X-plane (bending plane)
and the upper half shows envelope in Y-plane.)
TABLE 4 Simulation results of the transmission using round collimators (30 π*mm*mrad emittance transport) and using asymmetric
collimators (100 π*mm*mrad emittance transport). Transmission values are from the cyclotron to different locations along the beamline
M1 M2 M3 Coupling point isocenter
Reference beam optics 10 ± 0.3% 1.47 ± 0.04% 0.23 ± 0.007% 0.22 ± 0.007% 0.13 ± 0.004%
New beam optics 15 ± 0.45% 5.5 ± 0.165% 1.22 ± 0.037% 1.2 ± 0.036% 0.72 ± 0.022%
optics was designed with TRANSPORT (envelopes
shown in Figure 5(b)),BDSIM has been used to estimate
the transmission along the beamline.
At monitor M2, losses of almost 94.5% in beam inten-
sity after the asymmetric emittance selection collima-
tors have been estimated, versus a loss of 98.5% with
the reference optics (Table 4). As asymmetric collima-
tion enables a larger emittance with an improved match-
ing to the acceptance of the following beamline, this
results in a higher transmission. As such, with an emit-
tance of 100 π*mm*mrad in both planes, we are able to
achieve 1.22% transmission through the ESS instead of
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0.23% in the reference beam optics. Similar to the refer-
ence beam optics, there are no losses between the end
of the ESS and the coupling point and for both cases,
transmission through the gantry is about 60%. With an
asymmetric collimation system, we thus predict an over-
all transmission from the cyclotron to the isocenter for
70 MeV beam of 0.72%, compared to 0.13% in the ref-
erence beam optics, corresponding to an increase of
almost a factor of 6 in beam current reaching the patient.
However, this comes at a cost on beam size with the
simulated beam size in the air for the reference optics at
isocenter being 11.2 ± 0.6 mm, whereas for the asym-
metric beam optics, beam size at isocenter is 17.2 ±
0.7 mm, representing an increase of about 50%. With
the new system, we could achieve a maximum of 6 nA
beam current at the isocenter for 70 MeV beam com-
pared to 1 nA with the reference beam optics.
4 DISCUSSION
We have demonstrated that an asymmetric collimator
system for emittance selection, aiming at selecting
asymmetric beam sizes and beam divergences follow-
ing the degrader in a cyclotron-based proton therapy
facility, can achieve substantially higher transmissions
for low-energy beams. This approach overcomes the
limitations of typically used circular collimators, by
separately matching horizontal and vertical emittances
to the acceptance of the downstream beamline. Using
this design based on asymmetric collimators, we have
shown that up to 100 π*mm*mrad emittance could be
transported in both planes through the beamline. In a
BDSIM simulation of the PSI PROSCAN beamline, we
have found that this approach increases the low-energy
transmission by almost a factor of 6 compared to ref-
erence beam optics. In the simulation, we assumed
that the new collimator system is located at the same
position as the current collimator system;such a change
could thus be implemented easily in clinical practice.
By comparing PSI’s system with other cyclotron-driven
proton therapy facilities, we expect that a similar asym-
metric collimator system will be applicable in other
cyclotron-based facilities to increase the transmission
for low-energy beams. However, the magnitude of the
transmission increase will be facility dependent due
to differences in distances, apertures, materials, and
cyclotron energies.
Using asymmetric collimators to minimize losses will
mostly improve the transmission at the lower energies
used in proton therapy. There might however be some
effects also at the higher energies. For these (e.g., in
the range 180–230 MeV), the beam size and divergence
after the degrader will be lower than the beam sizes
selected in the X-plane and the divergence selected in
the Y-plane using collimators C1 and C2, respectively.
Because of this, for high-energy beams,we will not com-
pletely fill the aperture of the collimators, resulting in dif-
ferent emittances in the X and Y planes. One way to
overcome this deviation is to increase the beam size
(e.g.,by magnetic defocusing) and divergence (either by
magnetic defocusing or by using a scattering foil made
of high-Z material) of the incoming beam before or in
the energy degrader. This will increase the beam size
and divergence of the high-energy beam, but will then
cover the collimators C1 and C2 compactly. In this way,
we will get the same emittance in both planes even for
high-energy beams, although this could result in a less-
optimal transmission of high-energy beams through the
collimator system. However, since higher energies nat-
urally have lower losses, the two effects will counteract
each other, thus reducing the otherwise large energy-
dependent variation of the beam intensity reaching the
patient.
Because of the higher emittance transported using
asymmetric collimators, the beam size at the isocenter
will be 1.5 times larger compared to the reference beam
optics, which will have an inevitable effect on the lateral
penumbra. However, this might only be a limitation for
static tumors as larger beam sizes might be useful in
the context of motion mitigation.44 Larger beam sizes
could also be of advantage by enabling a reduction of
the number of spots required to cover the target volume,
potentially shortening the total delivery time even fur-
ther,and might also provide even more robustness to the
treatment plan. The beam sizes obtained with the new
optics,anyway,are still acceptable from a clinical point of
view, since they are compatible with those used in other
facilities.45,46 However, the beam size at the isocenter is
dependent on gantry beam optics and it will be investi-
gated as a continuation of this work.
In addition to the asymmetric collimator, the choice of
degrader material also has an impact on the divergence
after the degrader and thus on transmission. For exam-
ple, degraders made of boron carbide20 or beryllium22
could bring an additional 20%–30% increase in trans-
mission with respect to a graphite degrader (one of the
most commonly used material). At PSI, we are investi-
gating the possibility of using a boron carbide degrader,
which, if combined with the asymmetric collimation sys-
tem presented here, could result in about a factor of 7
higher transmission with respect to the reference optics.
5 CONCLUSION
In summary, we have demonstrated that the transport
of higher emittance beams through the beamline can
substantially increase low-energy beam transmission
by improved matching of the beam emittance between
elliptically shaped emittance selection collimators and
improved beam optics with a larger resulting beam
size at the coupling point. The resulting improved dose
rates could improve the treatment of moving tumors,
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by extending proton therapy applications to a more effi-
cient implementation of breath-hold,gating,and rescan-
ning. Shorter delivery times will also allow an efficient
implementation of hypo-fractionation regimes and even-
tually contribute to reducing the proton therapy treat-
ment cost.47,48 It may also help to reach FLASH dose
rates. This approach therefore could open a wide range
of possibilities for both current and future proton therapy
practice.
ACKNOWLEDGMENTS
We thank Dr. Rudolf Doelling for his support in the
measurements. We acknowledge the help of the PSI
cyclotron operation group, PSI vacuum group, and PSI
radiation protection group. This work is funded by PSI’s
CROSS funding scheme.
CONFL ICT OF INTEREST
The authors declare that there is no conflict of interest
that could be perceived as prejudicing the impartiality of
the research reported.
DATA AVAILABL IL IT Y STAT E M E N T
The data will be available to interested researches upon
request and under a confidentiality agreement, as they
contain sensitive information about a PSI product.
REFERENCES
1. Pedroni E,Bacher R,Blattmann H,et al.The 200-Mev proton ther-
apy project at the Paul Scherrer Institute: conceptual design and
practical realization. Med Phys. 1995;22(1):37-53. https://doi.org/
10.1118/1.597522.
2. Lin S, Boehringer T, Coray A, Grossmann M, Pedroni E. More
than 10 years experience of beam monitoring with the Gantry
1 spot scanning proton therapy facility at PSI. Med Phys.
2009;36(11):5331-5340. https://doi.org/10.1118/1.3244034.
3. Lomax AJ, Bortfeld T, Goitein G, et al. A treatment planning
inter-comparison of proton and intensity modulated photon radio-
therapy. Radiother Oncol. 1999;51(3):257-271. https://doi.org/10.
1016/S0167-8140(99)00036-5.
4. Ladra MM, Edgington SK, Mahajan A, et al. A dosimetric com-
parison of proton and intensity modulated radiation therapy in
pediatric rhabdomyosarcoma patients enrolled on a prospec-
tive phase II proton study. Radiother Oncol. 2014;113(1):77-83.
https://doi.org/10.1016/j.radonc.2014.08.033.
5. Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary
malignancy risk following proton radiation therapy. Front Oncol.
2015;5(Nov):1-6. https://doi.org/10.3389/fonc.2015.00261.
6. Bert C, Grözinger SO, Rietzel E. Quantification of interplay
effects of scanned particle beams and moving targets.Phys Med
Biol. 2008;53(9):2253-2265. https://doi.org/10.1088/0031-9155/
53/9/003.
7. Seco J, Robertson D, Trofimov A, Paganetti H. Breathing inter-
play effects during proton beam scanning:simulation and statisti-
cal analysis. Phys Med Biol. 2009;54(14). https://doi.org/10.1088/
0031-9155/54/14/N01.
8. Phillips MH, Pedroni E, Blattmann H, Boehringer T, Coray
A, Scheib S. Effects of respiratory motion on dose unifor-
mity with a charged particle scanning method. Phys Med
Biol. 1992;37(1):223-234. https://doi.org/10.1088/0031-9155/37/
1/016.
9. Chang JY, Zhang X, Knopf A, et al. Consensus guidelines for
implementing pencil-beam scanning proton therapy for thoracic
malignancies on behalf of the PTCOG Thoracic and Lymphoma
Subcommittee. Int J Radiat Oncol Biol Phys. 2017;99(1):41-50.
https://doi.org/10.1016/j.ijrobp.2017.05.014.
10. Hanley J, Debois MM, Mah D, et al. Deep inspiration breath-
hold technique for lung tumors: the potential value of target
immobilization and reduced lung density in dose escalation. Int
J Radiat Oncol Biol Phys. 1999;45(3):603-611. https://doi.org/10.
1016/S0360-3016(99)00154-6.
11. Dueck J, Knopf AC, Lomax A, et al. Robustness of the voluntary
breath-hold approach for the treatment of peripheral lung tumors
using hypofractionated pencil beam scanning proton therapy. Int
J Radiat Oncol Biol Phys. 2016;95(1):534-541. https://doi.org/10.
1016/j.ijrobp.2015.11.015.
12. Mori S, Inaniwa T, Furukawa T, Zenklusen S, Shirai T, Noda
K. Effects of a difference in respiratory cycle between treat-
ment planning and irradiation for phase-controlled rescanning
and carbon pencil beam scanning. Br J Radiol. 2013;86(1028).
https://doi.org/10.1259/bjr.20130163.
13. Schätti A, Zakova M, Meer D, Lomax AJ. Experimental verifica-
tion of motion mitigation of discrete proton spot scanning by re-
scanning. Phys Med Biol. 2013;58(23):8555-8572. https://doi.org/
10.1088/0031-9155/58/23/8555.
14. Zenklusen SM, Pedroni E, Meer D. A study on repainting strate-
gies for treating moderately moving targets with proton pen-
cil beam scanning at the new gantry 2 at PSI. Phys Med
Biol. 2010;55(17):5103-5121. https://doi.org/10.1088/0031-9155/
55/17/014.
15. Klimpki G, Zhang Y, Fattori G, et al. The impact of pencil beam
scanning techniques on the effectiveness and efficiency of res-
canning moving targets. Phys Med Biol. 2018;63(14). https://doi.
org/10.1088/1361-6560/aacd27.
16. Ohara K, Okumura T, Akisada M, et al. Irradiation synchro-
nized with respiration gate. Int J Radiat Oncol Biol Phys.
1989;17(4):853-857. https://doi.org/10.1016/0360-3016(89)
90078-3.
17. Nesteruk KP, Psoroulas S. Flash irradiation with proton beams:
beam characteristics and their implications for beam diagnostics.
Appl Sci. 2021;11(5):1-11. https://doi.org/10.3390/app11052170.
18. Jolly S, Owen H, Schippers M, Welsch C. Technical challenges
for FLASH proton therapy.Phys Med.2020;78(September):71-82.
https://doi.org/10.1016/j.ejmp.2020.08.005.
19. van de Water S, Safai S, Schippers JM, Weber DC, Lomax
AJ. Towards FLASH proton therapy: the impact of treatment
planning and machine characteristics on achievable dose rates.
Acta Oncol (Madr). 2019;58(10):1463-1469. https://doi.org/10.
1080/0284186X.2019.1627416.
20. Gerbershagen A,Baumgarten C,Kiselev D,Van Der Meer R,Ris-
ters Y, Schippers M. Measurements and simulations of boron
carbide as degrader material for proton therapy. Phys Med
Biol.2016;61(14):N337-N348.https://doi.org/10.1088/0031-9155/
61/14/N337.
21. Anferov V. Energy degrader optimization for medical beam lines.
Nucl Instrum Methods Phys Res A.2003;496:222-227.https://doi.
org/10.1016/S0168-9002(02)01625-X.
22. Van Goethem MJ, Van Der Meer R, Reist HW, Schippers JM.
Geant4 simulations of proton beam transport through a car-
bon or beryllium degrader and following a beam line. Phys Med
Biol. 2009;54(19):5831-5846. https://doi.org/10.1088/0031-9155/
54/19/011.
23. Flanz J. B. Large medical gantries. Proceedings Particle Accel-
erator Conference, 1995, Vol.3, pp. 2004-2008. https://doi.org/10.
1109/PAC.1995.505434.
24. Yves J, Gantry comprising beam analyser for use in particle ther-
apy. US Patent 9,289,624 B2. 2010. https://patentswarm.com/
patents/US9289624B2.
10 NEW EMITTANCE SELECTION COLLIMATOR
25. Schippers JM. Beam-transport systems for particle therapy.
Cern Yellow Reports Sch Proc. 2017;1(May):241-252. 10.23730/
CYRSP-2017-001.241.
26. Chen W, Yang J, Qin B, et al. Transmission calculation and inten-
sity suppression for a proton therapy system. Nucl Instrum Meth-
ods Phys Res A. 2018;881:82-87. https://doi.org/10.1016/j.nima.
2017.10.047.
27. Zeng XH, Zheng JX, Song YT, et al. Beam optics study for
energy selection system of SC200 superconducting proton
cyclotron. Nucl Sci Tech. 2018;29(9):1-8. https://doi.org/10.1007/
s41365-018-0462-5.
28. Maradia V, Meer D, Giovannelli AC, et al. New gantry beam
optics solution for minimizing treatment time in cyclotron-
based proton therapy facilities. PTCOG 2021 Conference.
Particle Therapy Co-Operative Group; 2021. https://doi.org/10.
3929/ethz-b-000497120.
29. Maradia V, Meer D, Giovannelli HAC, et al. A novel beam
optics concept to maximize the transmission through cyclotron-
based proton therapy gantries. Proc IPAC2021. JACoW Pub-
lishing; 2477-2479. http://doi.org/10.18429/JACoW-IPAC2021-
TUPAB407.
30. Juargen D & Helmut P (2016). U.S. Patent Number
US2016314929A. Washington, DC: U.S. Patent and Trade-
mark Office.
31. Liang Z, Chen W, Qin B, Liu X, Liu K, Zha J. Design of the energy
selection system for proton therapy based on GEANT4*. CYC
2016-Proc 21st Int Conf Cyclotrons their Appl. 2016;2016:30-32.
32. Schippers JM, Dölling R, Duppich J, et al. The SC cyclotron
and beam lines of PSI’s new protontherapy facility PROSCAN.
Nucl Instrum Methods Phys Res B. 2007;261(suppl 1-2):773-776.
https://doi.org/10.1016/j.nimb.2007.04.052.
33. Agapov I, Blair GA, Malton S, Deacon L. BDSIM: a particle
tracking code for accelerator beam-line simulations including
particle–matter interactions. Nucl Instrum Methods Phys Res
A 2009;606(3):708-712. https://doi.org/10.1016/j.nima.2009.04.
040.
34. Brown KL, Carey DC, Iselin FC, Rothacker F. Transport, a Com-
puter Program for Designing Charged Particle Beam Transport
Systems. CERN; 1980. https://doi.org/10.5170/CERN-1980-004.
35. Nevay LJ, Boogert ST, Garcia-Morales H, et al. Beam delivery
simulation: BDSIM automatic Geant4 models of accelerators.
IPAC 2016: Proceedings of the 7th International Particle Accel-
erator Conference. 2016. Inspire;3098-3100.
36. Psoroulas S, Meer D, Oponowicz E, Owen H. Mean exci-
tation energy determination for Monte Carlo simulations
of boron carbide as degrader material for proton therapy.
Phys Med.2020;80(April):111-118.https://doi.org/10.1016/j.ejmp.
2020.09.017.
37. Jarlskog CZ, Paganetti H. Physics settings for using the Geant4
toolkit in proton therapy. IEEE Trans Nucl Sci. 2008;55(3):1018-
1025. https://doi.org/10.1109/TNS.2008.922816.
38. Grevillot L,Frisson T,Zahra N,et al.Optimization of GEANT4 set-
tings for proton pencil beam scanning simulations using GATE.
Nucl Instrum Methods Phys Res B. 2010;268(20):3295-3305.
https://doi.org/10.1016/j.nimb.2010.07.011.
39. Fuchs H, Vatnitsky S, Stock M, Georg D, Grevillot L. Evalua-
tion of GATE/Geant4 multiple Coulomb scattering algorithms for
a 160 MeV proton beam. Nucl Instrum Methods Phys Res B.
2017;410:122-126. https://doi.org/10.1016/j.nimb.2017.08.006.
40. Resch AF, Elia A, Fuchs H, et al. Evaluation of electromag-
netic and nuclear scattering models in GATE/Geant4 for pro-
ton therapy. Med Phys. 2019;46(5):2444-2456. https://doi.org/10.
1002/mp.13472.
41. Brun R, Rademakers F. ROOT: An object oriented data analysis
framework. Nucl Instrum Methods Phys Res A 2020;389:81-86.
42. MATLAB version 9.6.0.1072779 (R2019a). 2019.
43. Dölling R. Profile, current, and halo monitors of the PROSCAN
beam lines. AIP Conf Proc. 2004;732:244-252. https://doi.org/10.
1063/1.1831154.
44. Grassberger C, Dowdell S, Sharp G, Paganetti H. Motion miti-
gation for lung cancer patients treated with active scanning pro-
ton therapy. Med Phys. 2015;42(5):2462-2469. https://doi.org/10.
1118/1.4916662.
45. Almhagen E, Boersma DJ, Nyström H, Ahnesjö A. A beam model
for focused proton pencil beams.Phys Med 2018;52(June):27-32.
https://doi.org/10.1016/j.ejmp.2018.06.007.
46. Shamurailatpam D, Manikandan A, Ganapathy K, et al. Charac-
terization and performance evaluation of the first-proton therapy
facility in India. J Med Phys. 2020;45(2):59-65. https://doi.org/10.
4103/jmp.JMP_12_20.
47. Verma V, Mishra MV, Mehta MP. A systematic review of the cost
and cost-effectiveness studies of proton radiotherapy. Cancer.
2016;122. https://doi.org/10.1002/cncr.29882.
48. Lievens Y, Pijls-Johannesma M. Health economic contro-
versy and cost-effectiveness of proton therapy. Semin Radiat
Oncol. 2013;23(2):134-141. https://doi.org/10.1016/j.semradonc.
2012.11.005.
SUPPORTI NG I NFORMATI ON
Additional supporting information may be found in the
online version of the article at the publisher’s website.
How to cite this article: Maradia V, Meer D,
Weber DC, Lomax AJ, Schippers JM, Psoroulas
S. A new emittance selection system to maximize
beam transmission for low-energy beams in
cyclotron-based proton therapy facilities with
gantry. Med Phys. 2021;1-10.
https://doi.org/10.1002/mp.15278
